Pooling six trials and 3,459 adults, researchers found no extra stomach side effects at the higher dose, though they flag small liver enzyme rises to watch.
Recap by typeshit. Full story at BIOENGINEER.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
After so-called Ozempic face and Ozempic hair loss, the post says another digestive symptom is getting attention and may point to something more than discomfort.
A new episode of the Annals of Internal Medicine podcast looks at tirzepatide in type 2 diabetes treatment. Listen through for the full discussion.
Loading…